Prognostic impact of baseline inflammatory markers in patients with acute coronary syndromes treated with ticagrelor and clopidogrel.
Thomas M, James S, Becker R, Himmelmann A, Katus H, Cannon C, Steg P, Siegbahn A, Lakic T, Storey R, Wallentin L. Prognostic impact of baseline inflammatory markers in patients with acute coronary syndromes treated with ticagrelor and clopidogrel. European Heart Journal Acute Cardiovascular Care 2019 PMID: 33609104, DOI: 10.1177/2048872619878075.Peer-Reviewed Original ResearchWhite blood cell countBaseline inflammatory markersTicagrelor compared to clopidogrelBlood cell countInflammatory markersC-reactive proteinAcute coronary syndromePrimary endpointCardiovascular deathCell countNeutrophil countClinical outcomesAcute coronary syndrome treated with ticagrelorCoronary syndromeCardiovascular benefitsN-terminal pro-brain-type natriuretic peptideInterleukin-6Increased risk of adverse cardiovascular eventsQuartile of white blood cell countComposite of cardiovascular deathAssociated with clinical outcomesRisk of adverse cardiovascular eventsLevels of inflammatory markersAcute coronary syndrome patientsPLATO study